1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Kalos Therapeutics, Inc. to Present at February 2nd, 2012 BIOCOM's Event

Kalos Therapeutics, Inc. Co Founder George Colberg to Present at BIOCOM's Global Life Science Partnering Conference 2012, La Jolla, CA, USA,Thursday February 2nd, 2012 Being held at the Lodge at Torrey Pines in La Jolla CA

 
PRLog - Jan. 31, 2012 - SAN DIEGO -- George Colberg, Executive Chairman of Kalos, said, "We are very encouraged by our research results, particularly in light of new applications for our ANP peptide product in AMD. The potential new approach may allow for delivery via eye drop and in a preventative care setting.” Changing the entire market for treating age related blindness, without intravitreal injections. The Company will be introducing a recently discovered application of its therapy in Adult Macular Degeneration, (AMD) which may provide a therapeutic and prophylactic application in this eye disease.

The Company continues to move its core products forward  in virulent cancers like pancreatic and ovarian, in a unique manner eliminating chemo-related side effect while leveraging the natural effects of ANP peptides in the body, whereby producing a cytostatic approach to treating these cancers, while reducing pain and edema related to abdominal cancers.

About Kalos Therapeutics:  Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyperproliferative disorders.

Kalos is a uniquely positioned biomedical company whose family of peptide therapeutics has previous successful clinical experience in humans.  Kalos is pioneering an approach to treat cancer by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.

More information can be found on Kalos' web site at http://www.kalostherapeutics.com

Contact:
Kalos Therapeutics George Colberg, Executive Chairman 858-385-1290 or gcolberg@kalostpx.com

info@kalostpx.com

SOURCE:  Kalos Therapeutics, North America, California

INDUSTRY KEYWORDS: Biotechnology, Clinical Trials, Oncology, AMD, Pharmaceutical, Research, Health,

# # #

Kalos Therapeutics, Inc. is targeting diseases causedby an abnormally high growth rate of cells (hyperproliferation). Our strategy is to harness the natural antiproliferative activity of the (ANP)family of peptides controling cancer and AMD

--- End ---

Click to Share

Contact Email:
***@kalostpx.com Email Verified
Source:George Colberg
Phone:858-385-1290
Zip:92128
Location:San Diego - California - United States
Industry:Biotech, Science, Health
Tags:amd, oncology, cancer, biologics, peptides, cytostatic, ovarian, pancreatic, biomedical, pharmaceutical health
Shortcut:prlog.org/11786817
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share